215 related articles for article (PubMed ID: 17311345)
1. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
Oh WK; Proctor K; Nakabayashi M; Evan C; Tormey LK; Daskivich T; Antràs L; Smith M; Neary MP; Duh MS
Cancer; 2007 Mar; 109(6):1090-6. PubMed ID: 17311345
[TBL] [Abstract][Full Text] [Related]
2. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
Polascik TJ; Given RW; Metzger C; Julian SR; Vestal JC; Karlin GS; Barkley CS; Bilhartz DL; McWhorter LT; Lacerna LV
Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
[TBL] [Abstract][Full Text] [Related]
3. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
Saad F; Abrahamsson PA; Miller K
BJU Int; 2009 Dec; 104(11):1573-9. PubMed ID: 20053188
[TBL] [Abstract][Full Text] [Related]
4. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
[TBL] [Abstract][Full Text] [Related]
5. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
7. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model.
McDermott RS; Kloth DD; Wang H; Hudes GR; Langer CJ
J Support Oncol; 2006; 4(10):524-9. PubMed ID: 17136870
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
Ryan CW; Huo D; Demers LM; Beer TM; Lacerna LV
J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
[TBL] [Abstract][Full Text] [Related]
10. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
Coleman RE; Major P; Lipton A; Brown JE; Lee KA; Smith M; Saad F; Zheng M; Hei YJ; Seaman J; Cook R
J Clin Oncol; 2005 Aug; 23(22):4925-35. PubMed ID: 15983391
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
[TBL] [Abstract][Full Text] [Related]
13. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
14. Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid.
Spence MM; Hui RL; Chan J; Schottinger JE
Ann Pharmacother; 2010 Sep; 44(9):1384-8. PubMed ID: 20682850
[TBL] [Abstract][Full Text] [Related]
15. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
Saad F
Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events.
Sherer JT; Adamus AT
Pharmacotherapy; 2007 Feb; 27(2):207-17. PubMed ID: 17253911
[TBL] [Abstract][Full Text] [Related]
18. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
Vogel CL; Yanagihara RH; Wood AJ; Schnell FM; Henderson C; Kaplan BH; Purdy MH; Orlowski R; Decker JL; Lacerna L; Hohneker JA
Oncologist; 2004; 9(6):687-95. PubMed ID: 15561812
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Lipton A; Zheng M; Seaman J
Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
[TBL] [Abstract][Full Text] [Related]
20. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
